<DOC>
	<DOCNO>NCT00540332</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety tolerability palifermin incidence oral mucositis subject locally advanced head neck cancer receive postoperative radiotherapy .</brief_summary>
	<brief_title>A Study Palifermin Reduction Oral Mucositis Subjects With Locally Advanced Head Neck Cancer Receiving Postoperative Radiotherapy</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<criteria>History newly diagnose histologically confirm squamous cell carcinoma ( AJCC Stage II , III IVA ) involve either oral cavity , oropharynx , hypopharynx , larynx post surgical resection ( R0 R1 ) Candidates postoperative RTonly treatment schedule receive RT within 12 week surgery Eastern Cooperative Oncology Group ( ECOG ) performance status less equal 2 Urinary proteincreatinine ratio ( random sample , spot PCR ) â‰¤ 0.2 mg/mg Tumors lip , paranasal sinus , salivary gland , unknown primary tumor R2 resection margin Metastatic disease ( M1 ) Presence history primary malignancy , curatively treat situ cervical cancer , basal cell carcinoma skin without evidence disease &gt; 3 year History pancreatitis Prior radiotherapy site disease Prior chemotherapy require chemotherapy treatment phase study Prior treatment palifermin , fibroblast keratinocyte growth factor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Oncology</keyword>
	<keyword>KGF</keyword>
	<keyword>HNC</keyword>
	<keyword>head neck</keyword>
	<keyword>oral mucositis</keyword>
	<keyword>OM</keyword>
	<keyword>proteinurea</keyword>
	<keyword>palifermin</keyword>
	<keyword>clinical trial</keyword>
</DOC>